NKGen Biotech Korea Co ltd (182400)

KOSDAQ

Currency in KRW

3,670

0(0.00%)

Closed·02:29:59

Fair Value

Unlock Value

Day's Range

1,815

3,685

52 wk Range

1,815

3,685

182400 Income Statement

Assess the NKGen Biotech Korea Co ltd income statement, providing a detailed view of the company’s financial performance across activities. This statement outlines key financial figures such as revenue, expenses, operating income, and net income. Assess the 182400 net worth.

Period Ending:

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

2024

31/12

2025

31/12

Total Revenues

aa.aa

13,020.25

11,262.69

9,947.88

8,800.04

7,862.52

Total Revenues Growth

aa.aa

+25.54%

-13.5%

-11.67%

-11.54%

-10.65%

Cost Of Revenues

aa.aa

4,956.98

4,203.49

4,928.28

1,804.26

1,541.21

Gross Profit

aa.aa

8,063.27

7,059.2

5,019.6

6,995.78

6,321.3

Gross Profit Growth

aa.aa

+26.9%

-12.45%

-28.89%

+39.37%

-9.64%

Gross Profit Margin %

aa.aa

61.93%

62.68%

50.46%

79.5%

80.4%

Other Operating Expenses, Total

aa.aa

55,503.7

56,712.25

77,795.94

11,056.99

8,449.03

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+16.73%	+2.18%	+37.18%	-85.79%	-23.59%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	9,355.23	9,895.06	9,440.55	2,951.98	2,006.65
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	36,140.67	35,864.22	57,994.84	7,650.82	6,112.72
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	1,629.75	1,495.35	1,883.54	426.38	169.43

Operating Income

aa.aa

-47,440.43

-49,653.05

-72,776.34

-4,061.21

-2,127.72

Operating Income Growth

aa.aa

-15.16%

-4.66%

-46.57%

+94.42%

+47.61%

EBIT Margin %

aa.aa

-364.36%

-440.86%

-731.58%

-46.15%

-27.06%

Net Interest Expenses

aa.aa

156.9

285.09

-1,024.63

-1,203.07

-578.73

Net Interest Expenses Growth

aa.aa

+235.5%

+81.7%

-459.41%

-17.41%

+51.9%

Interest Expense, Total

aa.aa

-367.41

-200.66

-1,088.18

-1,756.84

-978.34

Interest And Investment Income

aa.aa

524.31

485.75

63.54

553.77

399.61

Other Non Operating Expenses, Total

aa.aa

-866.86

-7,181.35

56,139.49

-24,891.4

-6,722.09

EBT, Excl. Unusual Items

aa.aa

-48,150.39

-56,549.31

-17,661.48

-30,155.68

-9,428.55

Gain (Loss) On Sale Of Assets

aa.aa

-283.62

-176.34

-83.17

1,802.49

Other Unusual Items, Total

aa.aa

-111,424.12

-5,651.92

2,904.38

EBT, Incl. Unusual Items

aa.aa

-50,094.81

-56,658.4

-165,658.42

-36,759.56

-7,342.48

EBT, Incl. Unusual Items Growth

aa.aa

-16.13%

-13.1%

-192.38%

+77.81%

+80.03%

EBT, Incl. Unusual Items Margin

aa.aa

-384.75%

-503.06%

-1,665.26%

-417.72%

-93.39%

Income Tax Expense

aa.aa

984.16

-1,051.03

-12,066.24

182.06

Net Income to Company

aa.aa

-51,078.96

-55,607.37

-153,592.18

-36,941.62

-7,342.48

Minority Interest

aa.aa

742.88

2,102.64

41,499.28

Net Income

aa.aa

-50,336.08

-53,504.73

-112,092.9

-36,941.62

-7,342.48

Net Income Growth

aa.aa

-21.47%

-6.29%

-109.5%

+67.04%

+80.12%

Net Income Margin %

aa.aa

-386.6%

-475.06%

-1,126.8%

-419.79%

-93.39%

Preferred Dividend and Other Adjustments

aa.aa

Net Income to Common Excl. Extra Items

aa.aa

-50,336.08

-53,504.73

-112,092.9

-36,941.62

-7,342.48

Basic EPS - Continuing Operations

aa.aa

-3,371.76

-3,209

-6,562.17

-2,054

-161

Basic EPS - Continuing Operations Growth

aa.aa

-11.59%

+4.83%

-104.49%

+68.7%

+92.16%

Diluted EPS - Continuing Operations

aa.aa

-3,371.76

-3,211

-6,854.25

-2,054

-161

Diluted EPS - Continuing Operations Growth

aa.aa

-11.59%

+4.77%

-113.46%

+70.03%

+92.16%

Basic Weighted Average Shares Outstanding

aa.aa

14.93

16.67

17.08

17.99

45.61

Diluted Weighted Average Shares Outstanding

aa.aa

14.93

18.41

17.08

17.99

45.61

Dividend Per Share

aa.aa

Dividend Per Share Growth

aa.aa

EBITDA

aa.aa

-38,987.96

-40,148.71

-64,275.7

-4,033.34

-1,928.71

EBITDA Growth

aa.aa

-15.18%

-2.98%

-60.09%

+93.72%

+52.18%

EBITDA Margin %

aa.aa

-299.44%

-356.48%

-646.12%

-45.83%

-24.53%

EBIT

aa.aa

-47,440.43

-49,653.05

-72,776.34

-4,061.21

-2,127.72

* In Millions of KRW (except for per share items)

FAQ

What was NKGen Biotech Korea Co ltd’s revenue at year end?

At the end of the last reported fiscal year, NKGen Biotech Korea Co ltd (182400) recorded total revenue of 7,863 million KRW.

How much revenue did NKGen Biotech Korea Co ltd report in the most recent quarter?

In its most recent quarterly earnings report, NKGen Biotech Korea Co ltd posted revenue of 2,211 million KRW.

What was NKGen Biotech Korea Co ltd’s net income for the year?

For the full year, NKGen Biotech Korea Co ltd reported net income of -7,342 million KRW.

How much net income did NKGen Biotech Korea Co ltd post in the last quarter?

In the most recent quarter, NKGen Biotech Korea Co ltd (182400) posted net income of -783 million KRW.

What was NKGen Biotech Korea Co ltd’s gross profit for the year?

Gross profit for the year was reported at 6,321 million KRW.

How much gross profit did NKGen Biotech Korea Co ltd generate last quarter?

NKGen Biotech Korea Co ltd recorded gross profit of 1,632 million KRW in its latest quarterly report.

What was NKGen Biotech Korea Co ltd’s annual operating income?

For the full year, NKGen Biotech Korea Co ltd (182400) reported operating income of -2,128 million KRW.

What was NKGen Biotech Korea Co ltd’s operating income last quarter?

Quarterly operating income was -2,935 million KRW.

What was NKGen Biotech Korea Co ltd’s quarterly EBITDA?

In the latest quarter, EBITDA was reported at -2,841 million KRW.

What was the quarter-over-quarter change in EBITDA for NKGen Biotech Korea Co ltd?

EBITDA changed by -32,908% million KRW compared to the last quarter.

What is NKGen Biotech Korea Co ltd’s most recent gross profit margin?

The latest reported gross profit margin for NKGen Biotech Korea Co ltd (182400) is 74% million KRW.

What is NKGen Biotech Korea Co ltd’s most recent net income margin?

Net income margin based on recent financials is -35% million KRW.

What is NKGen Biotech Korea Co ltd’s most recent EBIT margin?

NKGen Biotech Korea Co ltd reported an EBIT margin of -133% million KRW based on current figures.

How did NKGen Biotech Korea Co ltd’s revenue change compared to the previous quarter?

Revenue changed by 0% million KRW compared to the prior quarter.

What was the quarter-over-quarter change in gross profit for NKGen Biotech Korea Co ltd?

In the latest quarter, gross profit changed by -10% million KRW from the previous quarter.

S&P/TSX

33,912.93

-42.18

-0.12%

S&P/TSX 60

1,975.86

-0.87

-0.04%

US 30

49,198.90

-291.9

-0.59%

US 500

7,098.80

-39.1

-0.55%

S&P 500 VIX

19.31

+0.39

+2.06%

DAX

24,155.45

-39.45

-0.16%

Dollar Index

98.657

+0.245

+0.25%

Market Movers

Name	Last	Chg. %	Vol.
TC Energy	83.43	+1.60%	8.20M
Enbridge	71.91	+1.48%	7.95M
Canadian Natural	62.21	+1.80%	7.15M
Bank of Montreal	207.66	+0.63%	4.64M
Suncor Energy	88.48	+2.03%	3.41M
Toronto Dominion Bank	143.82	+0.62%	3.35M
RBC	239.56	-0.03%	3.34M

Name	Last	Chg. %	Vol.
Nirvana Life Sciences	0.04	+700.00%	11.33K
PeakBirch Logic	0.030	+500.00%	1.32K
Irwin Naturals	0.30	+150.00%	3.24K
Global Health Clinics	0.070	+133.33%	5.00K
MX Gold Corp	0.0450	+125.00%	6.65K
Green Scientific Labs Holdings	0.06	+120.00%	15.00K
Spod Lithium	0.01	+100.00%	2.64K

Name	Last	Chg. %	Vol.
New Frontier Ventures	0.030	-68.42%	13.00K
Noble Iron	0.0100	-66.67%	81.52K
Mayfair Acquisition	0.02	-60.00%	23.00K
CordovaCann	0.0150	-57.14%	22.00K
Portofino Resources	0.0050	-50.00%	22.84K
Molecule Holdings	0.005	-50.00%	20.11K
Albert Labs International	0.005	-50.00%	1.00K

Trending Stocks

Name	Last	Chg. %	Vol.
Canopy Growth	1.650	-12.70%	13.13M
Air Canada	18.26	-0.16%	2.46M
Celestica Inc.	537.48	-2.24%	497.21K
Hut 8	108.010	-2.13%	891.37K
Canadian Natural	62.21	+1.80%	7.15M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaa Aaa	5.18	+61.02%	8.34
Aaaaaa Aaaaaaaa A	43.34	+51.02%	65.45
Aaaaaaaaaaa	100.04	+49.29%	149.35
Aaaaaa Aaa Aaaaa	23.06	+42.56%	32.87
Aaaa Aaaaaaa Aaaa	6.78	+41.97%	9.63
Aaaaa Aa Aaaaa	258.80	+40.34%	363.20
Aaaaaa Aaaaa	10.72	+40.07%	15.02

Name	Last	Upside	Fair Value
Aaaa Aaa	5.18	+61.02%	8.34
Aaaaaa Aaaaaaaa A	43.34	+51.02%	65.45
Aaaaaaaaaaa	100.04	+49.29%	149.35
Aaaaaa Aaa Aaaaa	23.06	+42.56%	32.87
Aaaa Aaaaaaa Aaaa	6.78	+41.97%	9.63
Aaaaa Aa Aaaaa	258.80	+40.34%	363.20
Aaaaaa Aaaaa	10.72	+40.07%	15.02

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Popular Searches

Please try another search

NKGen Biotech Korea Co ltd (182400)

182400 Income Statement

FAQ

What was NKGen Biotech Korea Co ltd’s revenue at year end?

How much revenue did NKGen Biotech Korea Co ltd report in the most recent quarter?

What was NKGen Biotech Korea Co ltd’s net income for the year?

How much net income did NKGen Biotech Korea Co ltd post in the last quarter?

What was NKGen Biotech Korea Co ltd’s gross profit for the year?

How much gross profit did NKGen Biotech Korea Co ltd generate last quarter?

What was NKGen Biotech Korea Co ltd’s annual operating income?

What was NKGen Biotech Korea Co ltd’s operating income last quarter?

What was NKGen Biotech Korea Co ltd’s quarterly EBITDA?

What was the quarter-over-quarter change in EBITDA for NKGen Biotech Korea Co ltd?

What is NKGen Biotech Korea Co ltd’s most recent gross profit margin?

What is NKGen Biotech Korea Co ltd’s most recent net income margin?

What is NKGen Biotech Korea Co ltd’s most recent EBIT margin?

How did NKGen Biotech Korea Co ltd’s revenue change compared to the previous quarter?

What was the quarter-over-quarter change in gross profit for NKGen Biotech Korea Co ltd?

Trending Stocks